What Investors Find in Diligence — And What Kills Deals

Every founder who has been through a capital raise or M&A process has a story about what came up in diligence. Most of them are preventable. Some of them are fatal. All of them are less damaging when you know they're coming.

Having sat on both sides of the table — running diligence as an investor and preparing companies for it as an advisor — here is an honest account of what actually gets found, and what actually kills deals.

What investors are actually looking for

The purpose of diligence is not to find reasons to say no. It's to validate the story you've told, size the risks you haven't mentioned, and build enough conviction to deploy capital. A good diligence process is collaborative. A bad one is adversarial. The tone is usually set by how well-prepared the company is.

Investors are looking at four things simultaneously: the quality of the business, the quality of the numbers, the quality of the team, and the quality of the information. That last one is underrated. A company that produces organized, accurate information quickly signals competence and control. A company that can't produce a clean cap table in 48 hours signals the opposite.

What actually comes up

Revenue quality problems are the most common. This includes: customer concentration that wasn't disclosed upfront (one customer is 35% of revenue), contract terms that are weaker than presented (annual contracts that are actually cancellable with 30 days notice), revenue that was recognized in a period it wasn't earned, and churn figures that exclude certain customer types or contract structures. Investors model forward from your revenue base. If the base is shakier than it looked, the model changes.

Team and organizational issues surface more often than founders expect. Gaps in the leadership team that the founder hasn't acknowledged. Key person dependencies — the one engineer who built the product and is showing signs of leaving. Compensation structures that are out of market and create retention risk. Equity that was never formally issued. Employment agreements that are missing or inconsistent.

A company that produces organized, accurate information quickly signals competence and control.

IP and legal issues are a reliable source of deal complications. Who owns the IP? Was it built by contractors who signed proper assignment agreements? Is there open-source code embedded in the product that creates licensing obligations? Are customer contracts assignable in an acquisition? These questions don't usually kill deals on their own, but they slow them down and introduce negotiating leverage for the other side.

Data and privacy issues have grown significantly over the last five years. GDPR and CCPA compliance gaps, user data practices that weren't documented, data collection that exceeds what users consented to — these have moved from minor footnotes to material diligence items, especially for consumer-facing companies and companies that license data to third parties.

What actually kills deals

Discovery of material misrepresentation. Not omission — active misrepresentation. A company that overstated revenue in its pitch materials, mischaracterized customer relationships, or described a product capability that doesn't exist. This is rare, but when it happens the deal dies and the relationship ends permanently.

Unresolvable cap table problems. Missing signatures, disputed equity, convertibles that weren't accounted for in the capitalization. These create legal exposure for investors that most aren't willing to take on without resolution — and resolution takes time that live processes don't have.

Founder conflict. A co-founder dispute that surfaces during diligence, unresolved and adversarial, is one of the most reliable deal-killers in early-stage investing. Investors are backing a team. Evidence that the team is fractured undermines the entire investment thesis.

Revenue concentration combined with relationship risk. If 40% of revenue comes from one customer and that customer's champion at the company recently left — that's a different risk profile than it looked like in the pitch. Not always fatal, but it changes valuation and sometimes changes the decision.

What you can do about it

Run your own diligence before you go to market. Not a self-assessment — a genuine adversarial review of your business by someone who will write you a memo about what they found. It's uncomfortable. It's also the most useful thing you can do in the six months before a raise or sale.

The goal is not perfection. Every business has issues. The goal is to know what's there, fix what's fixable, contextualize what isn't, and walk into the process without surprises. Investors expect imperfection. What they don't accept is being caught off guard by something the founder knew about and didn't disclose.

Diligence doesn't kill deals. Surprises do. Know your business thoroughly enough that nothing a professional investor finds surprises you.